Liu Y.,Zhengzhou University |
Wu J.-R.,Xiangfan City Central Hospital |
Gao Y.-X.,Zhengzhou University
Journal of Xi'an Jiaotong University (Medical Sciences) | Year: 2011
Objective: In order to provide evidence for early diagnosis, prognosis prediction and new treatment of lung cancer, we analyze the immune escape of the Fas/FasL system in the carcinogenesis and progress of non-small cell lung cancer (NSCLC). Methods: Immunohisochemistry (IHC) method was used to determine the expression of Fas/FasL protein in NSCLC and normal lung tissues; CD45RO antibody and TUNEL technique were used to detect the tumor infiltrating lymphocytes (TILs) and apoptosis respectively. Results: Fas expression was found to be significantly reduced in cancer tissues, and it was correlated with the degree of tissue differentiation. There was a high level of FasL expression in cancer tissues. The expression rate of FasL was correlated with the cell type and lymph node metastasis, and negatively correlated with TIL infiltration degree. Fas expression had no association with the apoptosis level of cancer cells. Conclusion: Reduced or absent expression of Fas and increased FasL expression are common in NSCLC tissues, which leads to the escape of cancer cells from immunosurveillance and thus the carcinogenesis and development of NSCLC.
Zhang F.,Fudan University |
Ge J.,Fudan University |
Qian J.,Fudan University |
Ge L.,Fudan University |
And 95 more authors.
EuroIntervention | Year: 2012
Aims: The FOCUS registry is a prospective, multicentre, web-based programme designed to collect clinical outcome data from real-world patients receiving the second-generation cobalt-chromium sirolimus-eluting stent (CoCr-SES). Methods and results: From March 2009 to February 2010, a total of 5,084 patients from 83 centres who were eligible to receive CoCr-SES were enrolled in the FOCUS registry. The primary endpoint was 12-month major adverse cardiac events (MACE, defined as the composite of cardiac death, myocardial infarction [MI], and target vessel revascularisation [TVR]). One-year data were available for 5,013 (98.6%) of the 5,084 patients enrolled. The primary endpoint occurred in 174 (3.47%) of 5,013 patients, consisting of 43 (0.86%) cardiac deaths, 132 (2.63%) MI, and 46 (0.92%) TVR. According to the Academic Research Consortium definition, definite and probable stent thrombosis (ST) occurred in 0.52% (26/5,013) of patients, including 19 cases of early ST and 7 of late ST. The 12-month MACE rates were 3.73% and 2.60% for extended-use and standard-use patients, respectively (p=0.065). Conclusions: The second-generation CoCr-SES was associated with low rates of 12-month MACE and ST in a broad spectrum of patients, thereby confirming the clinical safety and efficacy of this stent in a real-world setting. © Europa Digital & Publishing 2012. All rights reserved.